Avaleht/Aktsiad/ATYR

ATYR

USD

aTyr Pharma Inc. Common Stock

$5.395-0.155 (-2.793%)

Reaalajas hind

Healthcare

Biotehnoloogia

Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad

Ettevõtte fundamentaalnäitajad

Kauplemisstatistika

Turunäitajad

Avatud

$5.550

Kõrge

$5.749

Madal

$5.330

Maht

2.00M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

480.2M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

1.63M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $1.42Praegune $5.395Kõrge $5.98

Seotud uudised

4. juuni 2025 · 15:45

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.

Vaata rohkem

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

4. juuni 2025 · 12:00

GlobeNewswire

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well

Vaata rohkem

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

19. mai 2025 · 12:00

GlobeNewswire

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world

Vaata rohkem

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

19. mai 2025 · 11:10

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.

Vaata rohkem

16. mai 2025 · 20:01

GlobeNewswire

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from

Vaata rohkem